Top Markets
Coin of the day
Acura Pharmaceuticals, Inc. Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

ACUR
Rangering i aksjer #41977
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to... Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the company's operations are headquartered in Palatine, Illinois.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$6.60K
Endring (1 dag)
-50.00%
Endring (1 år)
-80.00%
Land
US
Handel Acura Pharmaceuticals, Inc. (ACUR)

Kategori

Historikk for aksjesplitt for Acura Pharmaceuticals, Inc. (ACUR)
Aksjen Acura Pharmaceuticals, Inc. (symbol: ACUR) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Aug 13, 2026.
Én ACUR-aksje kjøpt før Aug 13, 2026 tilsvarer i dag 0 ACUR-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter